Sage Therapeutics (NASDAQ:SAGE) Posts Earnings Results, Misses Expectations By $0.02 EPS

Sage Therapeutics (NASDAQ:SAGE) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02), Zacks reports. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%.

Sage Therapeutics Trading Down 1.0 %

Shares of SAGE stock opened at $7.19 on Wednesday. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $27.39. The business’s 50 day moving average is $6.28 and its two-hundred day moving average is $6.96.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. TD Cowen reduced their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Thursday, November 21st. StockNews.com lowered shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Piper Sandler dropped their price objective on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective on the stock in a report on Thursday, November 21st. Finally, Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.53.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.